Clinicopathologic Features of 53 Patients with NSCLC
| Characteristic | Data |
| Mean age ± SD (y) | 58.5 ± 9.5 |
| Sex (n) | |
| Male | 39 (73.6%) |
| Female | 14 (26.4%) |
| Stage (n) | |
| IIIA | 28 (52.8%) |
| IIIB | 25 (47.2%) |
| Location (n) | |
| Right | 39 (73.6%) |
| Left | 14 (26.4%) |
| Pathologic type (n) | |
| Adenocarcinoma | 19 (35.8%) |
| Squamous cell carcinoma | 30 (56.6%) |
| Other | 4 (7.6%) |
| Chemotherapy (n) | |
| Cisplatin/gemcitabine | 16 (30.2%) |
| Cisplatin/docetaxel | 15 (28.3%) |
| Cisplatin/vinorelbine | 9 (17.0%) |
| Cisplatin/pemetrexed | 13 (24.5%) |
| RECIST (n) | |
| Complete response | 5 (9.4%) |
| Partial response | 28 (52.8%) |
| Stable disease | 17 (32.1%) |
| Progressive disease | 3 (5.7%) |
| Mean radiotherapy dose ± SD (Gy) | 67.5 ± 5.0 |
RECIST = Response Evaluation Criteria in Solid Tumors.